Xenikos
Developing a novel therapy that aims to reset the immune system of patients suffering from serious immune diseases or rejection after transplantation. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
AUD204—306m (Dealroom.co estimates May 2018.)
Company register number 09206362
Nijmegen Gelderland (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€3.6m | Series A | ||
€1.9m | Debt | ||
€30.0m | Series B | ||
€40.0m | Debt | ||
* | €2.5m | Grant | |
N/A | Early VC | ||
Total Funding | AUD61.4m |
Related Content
Recent News about Xenikos
EditMore about Xenikos
EditDeveloper of anti-T-cell antibodies designed to provide immunotherapy medicines to help restore patients' health. The company uses a therapeutic tool for resetting the body's immune system which once injected into the body, specifically identifies and eliminates adult T cells, with a strong preference for the activated ones, enabling the medical community to optimize treatment outcomes associated with serious immune diseases.
Keywords: Pharmaceuticals and Biotechnology, Drug Development, Drug Development Firm, Drug Development Unit, Immune System, Immunotherapy Company, Immunotherapy Drugs, Immunotherapy Trials.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.